Stay updated on Pembrolizumab in Endometrial Cancer Clinical Trial
Sign up to get notified when there's something new on the Pembrolizumab in Endometrial Cancer Clinical Trial page.

Latest updates to the Pembrolizumab in Endometrial Cancer Clinical Trial page
- Check4 days agoNo Change Detected
- Check11 days agoChange DetectedAdded the page revision tag 'Revision: v3.4.3' and removed the previous 'Revision: v3.4.2' tag.SummaryDifference0.1%

- Check18 days agoNo Change Detected
- Check32 days agoChange DetectedPage revision updated from v3.4.1 to v3.4.2. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check39 days agoChange DetectedRevision updated from v3.4.0 to v3.4.1 on the page footer; no substantive changes to study data, eligibility criteria, or results are evident. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check61 days agoChange DetectedThe page's revision label updates from v3.3.3 to v3.3.4. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check83 days agoChange DetectedAdded a Locations section listing Connecticut as a study site and removed the older Connecticut Locations entry and the HHS Vulnerability Disclosure in the prior revision.SummaryDifference0.2%

- Check106 days agoChange DetectedPage revision updated from v3.3.1 to v3.3.2 with no visible changes to study content or layout. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

Stay in the know with updates to Pembrolizumab in Endometrial Cancer Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pembrolizumab in Endometrial Cancer Clinical Trial page.